Physician

Elie Fahed, M.D.

According to 2025 Medicare claims, Elie Fahed, M.D. (NPI: 1356492482) practices medical oncology in the Casper, WY market, with the plurality of this provider's patient population coming from Natrona, WY. This provider's primary affiliated billing organization is ROCKY MOUNTAIN ONCOLOGY CENTER, LLC (NPI: 1003862723; TIN: 731684200) and primary practice location at 82609-4293.

Fahed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 646 traditional Medicare patients, billed 245,943 HCPCS/CPT codes, and received $6,012,353 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 881 prescription claims across 177 beneficiaries totaling $2,537,067 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 71 claims. Open Payments data shows 199 records totaling $47,264. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $2,286,755 to $6,012,353. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $738,793 to $2,537,067. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $13,309 to $1,457.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	449	177,371	$2,286,755
2016	567	174,373	$2,351,257
2017	604	137,907	$2,373,607
2018	601	216,185	$3,509,598
2019	642	279,815	$4,273,747
2020	593	224,657	$3,196,996
2021	611	223,442	$3,244,937
2022	594	301,976	$4,650,208
2023	638	318,533	$5,523,267
2024	646	245,943	$6,012,353

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	113	758	$738,793
2016	111	722	$822,180
2017	113	678	$924,367
2018	133	929	$1,763,675
2019	140	901	$1,623,978
2020	144	866	$1,538,395
2021	156	708	$800,594
2022	190	932	$1,820,094
2023	189	953	$1,451,039
2024	177	881	$2,537,067

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	27	176	$30,108
2016	N/R	114	$26,078
2017	N/R	65	$9,211
2018	N/R	50	$8,338
2019	N/R	44	$5,180
2020	N/R	69	$4,819
2021	N/R	78	$5,258
2022	N/R	48	$2,206
2023	N/R	42	$7,284
2024	N/R	71	$3,130

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	239	603	$107
80053	Blood test, comprehensive group of blood chemicals	327	1,090	$10
36415	Insertion of needle into vein for collection of blood sample	356	1,050	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	251	1,105	$8
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	223	461	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	51	1,428	$818,203
Revlimid	Lenalidomide	23	644	$420,509
Cabometyx	Cabozantinib S-Malate	13	390	$330,322
Verzenio	Abemaciclib	20	560	$300,574
Eliquis	Apixaban	43	2,385	$45,543

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$1,457
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$1,071
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$452
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	199	$47,264	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Elie Fahed, M.D.?

Tedicare shows public-source Medicare data for Elie Fahed, M.D. (NPI 1356492482), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Elie Fahed, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Elie Fahed, M.D.?

Elie Fahed, M.D. is linked to ROCKY MOUNTAIN ONCOLOGY CENTER, LLC (billing NPI 1003862723) in the available physician profile data.

Does Elie Fahed, M.D. have Open Payments data?

Elie Fahed, M.D. has 199 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.